KindredBio Announces Submission of European Medicines Agency Filing for Mirataz™

San Francisco, CA (December 21, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the European Marketing Authorization application for Mirataz™ (mirtazapine transdermal gel) has been submitted to the European Medicines Agency (EMA). The EMA has accepted the submission for review, with the […]

KindredBio Announces Positive Results from Pivotal Study of Zimeta Oral for Fever in Horses

San Francisco, CA (December 4, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field effectiveness study of Zimeta™ (dipyrone oral gel) for the control of pyrexia (fever) in horses. This study was a multicenter, randomized, blinded, placebo-controlled […]

Kindred Biosciences Announces Third Quarter 2017 Financial Results

San Francisco, CA (November 7, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2017 and provided updates on its programs. “We continue to look forward to the upcoming approval of our lead product candidates, […]

Kindred Biosciences to Announce Third Quarter 2017 Financial Results

Kindred Biosciences to Announce Third Quarter 2017 Financial Results Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Tuesday, November 7, 2017 San Francisco, CA (October 11, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today […]

Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference

San Francisco, CA (October 5, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Chief Operating Officer and Co-founder, will participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference, being held on October 11, 2017 in New York City. The event […]